Skip to Content

Axsome Therapeutics Inc AXSM

Morningstar Rating
$85.42 +3.32 (4.04%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AXSM is trading at a 471% premium.
Price
$81.79
Fair Value
$222.56
Uncertainty
Very High
1-Star Price
$418.98
5-Star Price
$77.13
Economic Moat
Flcx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AXSM is a good fit for your portfolio.

Trading Information

Previous Close Price
$82.10
Day Range
$82.6686.27
52-Week Range
$55.0898.34
Bid/Ask
$85.27 / $85.59
Market Cap
$4.06 Bil
Volume/Avg
367,258 / 704,037

Key Statistics

Price/Earnings (Normalized)
Price/Sales
15.18
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
569

Comparables

Valuation

Metric
AXSM
SLRN
GBIO
Price/Earnings (Normalized)
Price/Book Value
27.071.001.42
Price/Sales
15.1818.69
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AXSM
SLRN
GBIO
Quick Ratio
3.0113.087.75
Current Ratio
3.2013.278.01
Interest Coverage
−55.54
Quick Ratio
AXSM
SLRN
GBIO

Profitability

Metric
AXSM
SLRN
GBIO
Return on Assets (Normalized)
−32.80%−28.15%−23.97%
Return on Equity (Normalized)
−90.18%−35.30%−40.92%
Return on Invested Capital (Normalized)
−46.12%−41.97%−33.29%
Return on Assets
AXSM
SLRN
GBIO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
TxnpdxwbhRwfc$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
HdmyzkjlDhlnhd$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
KnwptfdxHjyhtsy$117.6 Bil
Moderna Inc
MRNA
XrsqwxgLccc$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
HzjfhspKytvgqz$29.9 Bil
argenx SE ADR
ARGX
WpjhhypqnZzrl$27.7 Bil
BioNTech SE ADR
BNTX
XkbymmlpXfwy$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
QqsjqnpmNnrrhz$15.8 Bil
United Therapeutics Corp
UTHR
BgjjwjjwrTbcht$14.6 Bil
Incyte Corp
INCY
MdqmvzddKzxdcl$12.9 Bil

Sponsor Center